Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors
June 19 2017 - 7:00AM
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders, today
announced the appointment of Myrtle Potter to its Board of
Directors. Ms. Potter is the Chief Executive Officer and Founder of
Myrtle Potter & Company, a healthcare and life science advisory
firm. Ms. Potter previously served as the President, Commercial
Operations and Chief Operating Officer of Genentech, and held
executive operating positions at Bristol-Myers Squibb and Merck.
“Myrtle Potter is a recognized healthcare leader
with extensive experience and unparalleled success in
commercializing numerous innovative medicines,” said Herriot
Tabuteau, M.D., Chief Executive Officer and Chairman of the Board
of Axsome. “We are extremely pleased to welcome her to our Board.
Her commercialization, operational, strategic, and business
development expertise will be of substantial benefit to Axsome as
our AXS-02 and AXS-05 product candidates advance towards pivotal
data readouts.”
“I am thrilled to join Axsome’s Board of
Directors,” said Ms. Potter. “The Company’s diversified clinical
pipeline has the potential to generate differentiated therapeutics
for multiple serious CNS and chronic pain conditions with currently
limited treatment options. I am eager to start working with my
fellow Axsome Board members and look forward to supporting the
management team to serve the needs of patients and maximize the
value of the Company’s product candidate portfolio for the benefit
of shareholders.”
Ms. Potter was President, Commercial Operations
and Chief Operating Officer of Genentech from 2000 to 2005, where
she also served on the Executive Committee and was Co-Chair of the
Product Portfolio Committee. At Genentech Ms. Potter led the
commercialization of a number of products including Avastin™,
Rituxan™, Herceptin™, Tarceva™, Xolair™, Nutropin™, Activase™, and
TNkase™. Prior to joining Genentech, Ms. Potter was President of
Bristol-Myers Squibb’s $3.5 billion, 3,500-person U.S.
Cardiovascular and Metabolic Business. Before Bristol-Myers Squibb,
Ms. Potter worked at Merck & Co. for fourteen years in roles of
increasing responsibility, including Vice President of an $800
million U.S. pharmaceutical business unit. While at Merck, she
started the joint venture entity Astra Merck, which through merger,
later became AstraZeneca. She began her career with Procter and
Gamble Patient Care Products.
Ms. Potter currently serves on the Board of
Directors of Liberty Mutual Holding Company, Rite Aid Corporation,
Insmed, and Proteus Digital Health. She is also on the Board of
Trustees of The University of Chicago and previously served on the
boards of Everyday Health, Medco Health Solutions and Amazon.com.
Ms. Potter holds a Bachelor of Arts Degree from The University of
Chicago.
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders for which
there are limited treatment options. Axsome’s product candidate
portfolio includes two late-stage candidates, AXS-05 and AXS-02.
AXS-05 is currently in a Phase 3 trial in treatment resistant
depression (TRD), and a Phase 2/3 trial in agitation in patients
with Alzheimer’s disease (AD) is planned. AXS-02 is currently in
Phase 3 trials in complex regional pain syndrome (CRPS) and knee
osteoarthritis (OA) associated with bone marrow lesions (BMLs) with
an additional Phase 3 trial planned in chronic low back pain (CLBP)
associated with Modic changes (MCs). AXS-05 and AXS-02 are
investigational drug products not approved by the FDA. For more
information, please visit the company website at www.axsome.com.
The company may occasionally disseminate material, nonpublic
information on the company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, interim
analyses and completion of the trials; the timing of and our
ability to obtain and maintain U.S. Food and Drug Administration or
other regulatory authority approval of, or other action with
respect to, our product candidates; the Company’s ability to
successfully defend its intellectual property or obtain the
necessary licenses at a cost acceptable to the Company, if at all;
the successful implementation of the Company’s research and
development programs and collaborations; the success of the
Company’s license agreements; the acceptance by the market of the
Company’s product candidates, if approved; and other factors,
including general economic conditions and regulatory developments,
not within the Company’s control. The factors discussed herein
could cause actual results and developments to be materially
different from those expressed in or implied by such statements.
The forward-looking statements are made only as of the date of this
press release and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstance.
Axsome Contact:
Mark Jacobson
Vice President, Operations
Axsome Therapeutics, Inc.
25 Broadway, 9th Floor
New York, NY 10004
Tel: 212-332-3243
Email: mjacobson@axsome.com
www.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2024 to May 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From May 2023 to May 2024